
May 12, 2026 | When it comes to drug discovery, either you find a rare, clean target and everything clicks, or you spend a decade chasing biology that refuses to cooperate. Daniel Chen, M.D., Ph.D., founder and CEO of Synthetic Design Lab, makes the case for a different playbook: objective-driven protein engineering, where we start with the outcome and design biologics that can execute it with built-in logic. With host Andrew Bradbury, Chen unpacks the SYNTHBODY platform and what “multi-tier ...
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Episode: 84 - Martin Pacesa on BindCraft: An Automated Pipeline for De Novo Protein Binder Design

Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement

Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies?

Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research
Free AI-powered recaps of The Chain: Protein Engineering Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.